Communiqué de presse
Pivotal Phase 3 Data Showing Significant Improvements in Facial and Total Body Repigmentation with Ruxolitinib Cream (Opzelura™) in Vitiligo Published in New England Journal of Medicine
October 19, 2022 Data served as basis for recent FDA approval of ruxolitinib cream (Opzelura™) 1.5% for the topical treatment […]